1. Home
  2. REGN vs VRT Comparison

REGN vs VRT Comparison

Compare REGN & VRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Regeneron Pharmaceuticals Inc.

REGN

Regeneron Pharmaceuticals Inc.

HOLD

Current Price

$809.37

Market Cap

73.9B

Sector

Health Care

ML Signal

HOLD

Logo Vertiv Holdings LLC

VRT

Vertiv Holdings LLC

HOLD

Current Price

$171.69

Market Cap

63.8B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
REGN
VRT
Founded
1988
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
73.9B
63.8B
IPO Year
1991
N/A

Fundamental Metrics

Financial Performance
Metric
REGN
VRT
Price
$809.37
$171.69
Analyst Decision
Buy
Buy
Analyst Count
23
18
Target Price
$805.87
$190.13
AVG Volume (30 Days)
811.7K
6.5M
Earning Date
01-30-2026
02-11-2026
Dividend Yield
0.45%
0.14%
EPS Growth
2.88
77.20
EPS
41.59
2.65
Revenue
$14,247,800,000.00
$9,696,300,000.00
Revenue This Year
$1.99
$28.79
Revenue Next Year
$6.68
$20.53
P/E Ratio
$18.67
$65.96
Revenue Growth
2.89
28.75
52 Week Low
$476.49
$53.60
52 Week High
$792.77
$202.45

Technical Indicators

Market Signals
Indicator
REGN
VRT
Relative Strength Index (RSI) 68.64 52.14
Support Level $753.20 $162.21
Resistance Level $779.75 $183.25
Average True Range (ATR) 15.80 6.74
MACD -0.51 1.37
Stochastic Oscillator 93.24 68.01

Price Performance

Historical Comparison
REGN
VRT

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

About VRT Vertiv Holdings LLC

Vertiv has roots tracing back to 1946 when its founder, Ralph Liebert, developed an air-cooling system for mainframe data rooms. As computers started making their way into commercial applications in 1965, Liebert developed one of the first computer room air conditioning, or CRAC, units, enabling the precise control of temperature and humidity. The firm has slowly expanded its data center portfolio through internal product development and the acquisition of thermal and power management products like condensers, busways, and switches. Vertiv has global operations today; its products can be found in data centers in most regions throughout the world.

Share on Social Networks: